Sortilin Crystal Structure for Ligand Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for inhibiting the formation of ternary complexes between Sortilin, p75 NTR, and proneurotrophins like pro-NGF and proBDNF, which are involved in neuronal apoptosis, and for identifying ligands that can act as agonists or inhibitors for Sortilin, particularly for treating nervous system disorders.
Innovation Solution
The development of a crystal structure of Sortilin and methods for growing Sortilin crystals, allowing for the identification of ligands that bind to specific sites on Sortilin, including binding site 1, 2, and 3, using atomic coordinates and computer-aided modeling to design inhibitors that prevent the formation of these ternary complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to identify ligands for Sortilin, then the process is simple and quick, but the precision and reliability of ligand identification is insufficient
Solution Approach 1:
The patent applies preliminary action by determining the crystal structure of Sortilin in advance, which then serves as a foundation for subsequent ligand identification efforts. The crystal structure data (PDB ID: 1STL) is prepared and made available before ligand screening begins, allowing for more precise and reliable ligand identification through computer-aided modeling and docking studies rather than relying on less precise conventional methods.
2Reliability
If crystal structure determination methods are used, then ligand identification precision is improved, but the time required and manufacturing complexity increases
Solution Approach 1:
The crystal structure of Sortilin has been determined in advance and is available as PDB ID: 1STL, allowing subsequent ligand identification studies to proceed without repeating the time-consuming crystal structure determination process. This preliminary structural data enables reliable virtual screening and docking studies to be performed more efficiently.
Solution Approach 2:
The patent uses computer-aided modeling to create virtual representations of ligands and their interactions with Sortilin's binding sites. These computational models allow for efficient screening of potential ligands against the known crystal structure without requiring physical experimentation for each candidate, significantly reducing the time required while maintaining reliability.
3Object-affected harmful factors
If specific binding sites on Sortilin are targeted, then the effectiveness of ligand inhibition is improved, but the difficulty of detecting and measuring binding sites increases
Solution Approach 1:
The crystal structure determination has already identified and characterized the specific binding sites on Sortilin (including the Vps10p domain and other ligand-binding regions) before ligand screening begins. This preliminary structural information makes the binding sites accessible for targeted ligand design and virtual screening, rather than requiring de novo detection during the ligand identification process.
Solution Approach 2:
The patent replaces difficult physical measurements of binding site characteristics with computer-aided modeling and computational docking studies. These computational methods allow for efficient exploration and characterization of binding sites based on the known crystal structure, making the process more tractable than direct experimental measurement of each binding interaction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of ligands that can inhibit Sortilin's binding to proneurotrophins, potentially preventing neuronal apoptosis and providing therapeutic options for nervous system disorders by targeting specific binding sites on Sortilin.
Implementation Method 1
The three dimensional structure, described by the atomic coordinates obtained by X-ray crystallography of the human receptor Sortilin
Implementation Method 2
The disclosure further relates to methods for growing crystals of Sortilin
Data Source
Figure 1A~1E
Figure 2A~2E
Figure 3A~3D
AI summary
The present invention provides a Sortilin crystal and methods for growing said crystal. The invention furthermore provide methods for design of specific ligands based on the crystal structure of Sortilin. The present invention also relates to the preparation and use of such ligands for the preparation of a medicament for the treatment of disease, damage or disorders of the central and peripheral nervous systems.